Firm boundaries Flashcards

1
Q

What are the two ways of thinking about the scope of the firm?

A

Vertical and horizontal boundaries

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is meant by vertical boundaries?

A

This can be i.e. various production stages and this can be covered by the same or several different firms.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What is meant by horizontal boundaries?

A

We are staying at one stage but have to decide on how broad the scope of the product should be. e.g. covering several therapeutic areas or covering single markets.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What are benefits of vertical integration?

A
  • Technical economies from physical integration of processes
  • Avoid profit capture by powerful suppliers (demanding high prices) and distributors (insisting on lower purchase prices)
    -Avoiding search, contracting, monitoring and enforcement costs
  • Avoiding dependencies arising from relationship-specific investments
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What are costs of vertical integration?

A
  • Units may not achieve sufficient scale to produce efficiently
  • Managing structurally different business is difficult
  • Specialisation may allow for better development of unique capabilities
  • Incentive problems: vertical units may not remain competitive
  • Negative competitive effects: competing with customers
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Incentives for splitting up activities/outsourcing to other countries (veritcal):

A

If you don’t have the resources to have all the activities yourself. Networking effects. You can sell to many other countries rather than just yourself.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Incentives for integrating (vertical):

A

Making sure you are in control –> a fixed price for yourself. You are vulnerable to your own value chain - more dependent on previous steps. Another risk is that the sections do not really stay competitive bc you know you have your customer (the next in the supply chain) - cause everything is integrated.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What are the transaction costs?

A

1) Search costs: finding the right partners
2) Contracting costs: specifying the required parameters of a transaction (e.g. quality)
3) Monitoring and enforcement costs: monitoring partner’s compliance

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

The ‘make-or-buy’ decision is strongly driven by considerations of what?

A

Transaction costs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What can happen if you have an investment into relationship-specific assets?

A

This can be exploited by partner (opportunistic behaviour)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What is an ‘Hold-up’?

A

An action to exploit another party’s dependence

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

From where does hold-up arise from?

A

From relationship-specific investments: an asset is only useful in the context of the collaboration (sunk cost). Meaning one party imposes new, for the partner unfavourable, terms.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is the solution if specific investments cannot be avoided (in consideration to hold-ups)?

A

Detailed contracts or vertical integration. Both solutions are costly and contracts may not be enforceable.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Asset specificity:

A

Might be necessary to engage in a specific relationship where they only have value in this agreement (i.e. input cannot come from a different supplier)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Examples of vertical boundaries hold-up:

A

Public procurement –> a company says ‘oh it became more expensive’ while in the middle of building - then, what does that public do? Terminate the contract or just pay much extra.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Does doing R&D in-house in pharma/biotech have a positive or negative value to the company?

A

POSITIVE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Can the European Union prevent M&As (in relation to horizontal boundaries)?

A

European union can prevent an acquisition/merger if the market power, for the aquirer, after the M&A gets too big

–> sometimes the M&A will only be allowed during some specific conditions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

M&As enables a company of what (in relation to horizontal boundaries)?

A

1) seek ownership or increase control over a firm’s competitors through M&As among competitors
2) Economics of scale through size increase
3) Increasing market power

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

What are the three drivers for horizontal boundaries?

A
  • Horizontal integration without diversification
  • Diversification strategy
  • Geographic expansion
20
Q

What are the motives fro diversification?

A
  • Accessing new growth opportunity
  • Diversifying business risks
  • Economics of scope
  • Internal capital and labor markets
  • Economies from internalising transactions
21
Q

What are challenges of diversification?

A
  • Depending on ‘relatedness’: high complexity of running different businesses
  • Unclear strategic focus
  • Determining optimal investment decisions and resource allocations
  • Firm size increases associated with own inefficiencies
  • ‘Local empires’: managerial challenges
  • Customers might have trouble understanding the brand identity
22
Q

What is an example of a company within horizontal boundaries?

A

1) General Electric (GE); GE digital, GE healthcare, GE Power, GE capital etc.
2) Novozymes: bioenergy, leather, food&beverages, textile etc.

23
Q

Geo scope is a very simply said means

A

money overseas

24
Q

What are the different choices to take into consideration when entering a foreign market (in relation to geo scope)?

A
  • Role of country resources for competitive advantages: e.g. labor or energy costs, physical proximity to production inputs. Availability of resources: are local partners needed?
  • Tradability of product: import restrictions and regulation, complexity of product, necessity to adapt product
  • Transaction costs
  • Appropriability; can setting up foreign facilities increase risk of knowledge outflows
25
Q

Is the number M&As in biotech/pharma sector increasing or decreasing?

A

increasing

26
Q

What is the difference between a merger and an acquisition?

A

a merger is the combining of two organizations into an entirely new entity, while an acquisition is when a company absorbs another, but no new organization is created

27
Q

What are some motives related to engage in M&A transactions in biopharma?

A

1) Access to new technology
2) Response to industry-wide shocks (eg pharma productivity crisis)
3) Realising Economies of Scale and Scope; positive returns to size
4) Expansion to foreign markets: cross-border mergers to gain ability to do global product launches and to use local sales force
5) Increasing market power (but subject to antitrust regulation)
6) Tax optimisation

28
Q

What are some concrete challenges in M&A?

A

1) Too high acquisition premiums: buyer pays too much for acquisition target
2) Lacking fit I terms of organisational structure and culture
3) Difficult integration processes and problematic interpersonal communication: Key (scientific) employees may leave the firm
4) Overly optimistic expectations about possible synergies
5) Merger and subsequent integration process captures too much of managerial attention

29
Q

Relationships between firms can become source of…

A

competitive advantage

30
Q

What are the four potential sources of competitive advantage?

A

1) Relation-specific asset: developing assets unique to a collaboration
2) Knowledge sharing routines: effective knowledge transfer
3) Complementary Resources: benefiting from partners’ strength
4) Effective Governance: reducing transaction costs

31
Q

What are the different assets that can be ‘created’ in a relation-specific assets?

A

1) Site-specific investments: partner colocate and then benefit from physical proximity
2) Physical assets: transaction-specific capital investments (e.g. customised machines) that allow for product differentiation
3) Human asset specificity: developing human capital (skills, experience) in the context of the collaboration

32
Q

What goes in in knowledge-sharing routines?

A
  • Developing a specific absorptive capacity for the alliance
  • Incentives for sharing knowledge, eg. through monetary incentives or reciprocity
  • Transfer of tacit knowledge, e.g. through frequent face-to-face interactions
33
Q

What goes in complementary resources?

A
  • Partners combine their respectively unique resources in a complementary manner
  • Combined resources and capabilities that cannot be procured through different providers at the market place
  • Compatibility of organisational structures and processes essential precondition to emerge complementary resources
34
Q

What goes into Effective Governance?

A
  • Minimising transaction costs and opportunistic behaviour
  • Setting up legal contracts
  • Relying on self-enforcement (based on incentives to comply such as economic hostages, or informal ones such as reputation&trust)
35
Q

What are the main characteristics of trading patents?

A
  • Owner of a technology (licensor) grants other firm (licensee) access to a technology for commercialisation
  • Licensing can be seen as a transaction or a form of collaboration
  • Revenue and risk-sharing between licensor and licensee
  • Various forms: payment structures, cross-licensing, exclusivity of licence
36
Q

What are some aspects to consider for the scope of transaction for trading patents?

A
  • Additional know-how transfer?
  • Application: can the technology be used for multiple products?
  • Geographic scope: specific countries or regions?
  • Is the licensee allowed to sub-licence it?
  • Is the licensee encouraged to modify/advance the technology?
  • Provisions in anticipation of litigation risk
37
Q

What can supplying technologies enable?

A

1) Strength and scope of patent rights
2) Availability of downstream capabilities: production, marketing and distribution, regulatory experience
3) Generality of a technology: can a technology be applied in multiple product markets?
4) Strategic motives: licensing to encourage follow-on innovation by others, which then in turn can be accessed later

38
Q

A strategic alliance is…

A

.. a collaborative arrangement between firms to pursue agreed common goals

39
Q

What kind of alliances are there?

A
  • Strategic alliance, example: Novo Nordisk + Medtronic to develop this diabetes pen
  • Joint venture: may or may not involve equity participation
  • Bilateral arrangements of part of a network of inter-firm relationships
  • Exploiting complementarities
  • Accessing resources or acquiring them (learning)
40
Q

In a simple way, how to manage alliances?

A

Building trust and implementing effective knowledge-sharing and coordination routines

41
Q

What are some challenges of alliances?

A
  • Diverging goals of partners
  • International alliances: cultural differences and geographic distance
42
Q

CVC =

A

Corporate Venture Capital

43
Q

What are the motivations for corporations for CVC?

A
  • Access to new knowledge outside of core area but possibly relevant in future
  • Reduced resource commitment in comparison to acquisitions or internal R&D
  • Additional revenue through successful exits if own acquisition is not pursued
  • ‘Staying in touch’ with employee spin-offs
44
Q

What are the motivations for start-ups (besides funding) for CVC?

A
  • Access to business partners (CVC corporation but also customers thereof)
  • Possibly leveraging on R&D expertise of parent
  • Less pressure on timelines as compared to independent VC
45
Q

What are some disadvantages for start-ups to go with CVC?

A
  • Risk of knowledge spillovers
  • Hampering chances to establish relationships with other firms
  • Reduced monitoring by CVC (in comparison to VC)
46
Q

Determining the optimal firm boundaries is an important…..

A

Strategic decision